Exact Sciences (EXAS) – Research Analysts’ Weekly Ratings Changes

Exact Sciences (NASDAQ: EXAS) recently received a number of ratings updates from brokerages and research firms:

• 2/24/2025 – Exact Sciences had its price target raised by analysts at Scotiabank from $70.00 to $73.00. They now have a “sector outperform” rating on the stock.
• 2/20/2025 – Exact Sciences had its price target lowered by analysts at Barclays PLC from $70.00 to $65.00. They now have an “overweight” rating on the stock.
• 2/20/2025 – Exact Sciences had its “outperform” rating reaffirmed by analysts at William Blair.
• 2/20/2025 – Exact Sciences had its price target lowered by analysts at Bank of America Co. from $72.00 to $65.00. They now have a “buy” rating on the stock.
• 1/23/2025 – Exact Sciences is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $70.00 price target on the stock.
• 1/13/2025 – Exact Sciences had its “outperform” rating reaffirmed by analysts at William Blair.
• 1/13/2025 – Exact Sciences had its “buy” rating reaffirmed by analysts at Benchmark Co.. They now have a $65.00 price target on the stock.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS opened at $51.28 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The firm’s 50-day moving average price is $54.72 and its 200-day moving average price is $60.00. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a market cap of $9.53 billion, a PE ratio of -9.21 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of EXAS. Capital World Investors grew its stake in shares of Exact Sciences by 10.7% during the 4th quarter. Capital World Investors now owns 17,537,617 shares of the medical research company’s stock valued at $985,439,000 after purchasing an additional 1,696,321 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Exact Sciences by 74.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company’s stock worth $323,669,000 after buying an additional 2,462,165 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Exact Sciences by 25.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company’s stock worth $239,922,000 after buying an additional 876,985 shares during the last quarter. Geode Capital Management LLC grew its position in Exact Sciences by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company’s stock valued at $175,165,000 after buying an additional 16,828 shares during the period. Finally, Mackenzie Financial Corp increased its holdings in Exact Sciences by 107.7% during the fourth quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company’s stock valued at $164,037,000 after buying an additional 1,513,873 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.